CN111712573A - 针对骨硬化蛋白的适体及其用途 - Google Patents

针对骨硬化蛋白的适体及其用途 Download PDF

Info

Publication number
CN111712573A
CN111712573A CN201980012952.6A CN201980012952A CN111712573A CN 111712573 A CN111712573 A CN 111712573A CN 201980012952 A CN201980012952 A CN 201980012952A CN 111712573 A CN111712573 A CN 111712573A
Authority
CN
China
Prior art keywords
aptamer
sclerostin
modification
preferably less
aptscl56
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980012952.6A
Other languages
English (en)
Other versions
CN111712573B (zh
Inventor
张戈
于媛媛
倪帅健
何伊欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anpei Treatment Co ltd
Original Assignee
Anpei Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anpei Treatment Co ltd filed Critical Anpei Treatment Co ltd
Publication of CN111712573A publication Critical patent/CN111712573A/zh
Application granted granted Critical
Publication of CN111712573B publication Critical patent/CN111712573B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明涉及生物医药领域。具体而言，本发明涉及针对骨硬化蛋白的适体及其用途，特别是其用于治疗骨硬化蛋白相关疾病例如骨质疏松症中的用途。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201980012952.6A 2018-02-12 2019-02-11 针对骨硬化蛋白的适体及其用途 Active CN111712573B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018101456626 2018-02-12
CN201810145662 2018-02-12
PCT/CN2019/074764 WO2019154410A1 (zh) 2018-02-12 2019-02-11 针对骨硬化蛋白的适体及其用途

Publications (2)

Publication Number Publication Date
CN111712573A true CN111712573A (zh) 2020-09-25
CN111712573B CN111712573B (zh) 2023-10-20

Family

ID=67548808

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980012952.6A Active CN111712573B (zh) 2018-02-12 2019-02-11 针对骨硬化蛋白的适体及其用途

Country Status (5)

Country Link
US (1) US20210198672A1 (zh)
EP (1) EP3754021A4 (zh)
JP (1) JP7120531B2 (zh)
CN (1) CN111712573B (zh)
WO (1) WO2019154410A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454224A (zh) * 2019-02-11 2021-09-28 深圳欣沛生物医药技术服务有限公司 针对骨硬化蛋白的适体的诊断用途
CN114129587A (zh) * 2021-11-16 2022-03-04 北京大学口腔医学院 用于治疗骨质疏松症的纳米药物及其制备方法和应用
WO2023046147A1 (zh) * 2021-09-26 2023-03-30 安沛治疗有限公司 针对dkk1的适体及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240200081A1 (en) * 2021-03-25 2024-06-20 Aptacure Therapeutics Limited Nucleic acid molecule conjugate having prolonged in vivo half-life

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017008A1 (en) * 2005-06-10 2009-01-15 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
US20110294872A1 (en) * 2010-05-27 2011-12-01 The University Of Hong Kong High-affinity nucleic acid aptamers against sclerostin protein
CN103319596A (zh) * 2003-06-16 2013-09-25 优时比制造公司 用于增加骨矿化的组合物和方法
CN104039828A (zh) * 2011-12-28 2014-09-10 安进公司 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
EA015166B1 (ru) * 2003-06-16 2011-06-30 Ю-Си-Би Мэньюфэкчуринг, Инк. Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
EP3345607B1 (en) * 2006-12-29 2022-10-26 Ossifi-Mab LLC Methods of altering bone growth by administration of sost or wise antagonist or agonist
CN101957530B (zh) * 2009-07-17 2013-07-24 北京京东方光电科技有限公司 Tft-lcd阵列基板及其制造方法
EP3345915B1 (en) 2010-04-12 2021-11-24 Somalogic, Inc. 5-position modified pyrimidines and their use
CN103114147B (zh) * 2013-02-28 2015-09-23 上海交通大学 无固定点靶物质的适配体筛选方法
RS61158B1 (sr) * 2015-03-13 2021-01-29 Jiangsu Hengrui Medicine Co Anti-sklerostin antitelo, antigen vezujući fragment i njegova medicinska upotreba
WO2020163974A1 (zh) * 2019-02-11 2020-08-20 深圳欣沛生物医药技术服务有限公司 针对骨硬化蛋白的适体的诊断用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103319596A (zh) * 2003-06-16 2013-09-25 优时比制造公司 用于增加骨矿化的组合物和方法
US20090017008A1 (en) * 2005-06-10 2009-01-15 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
US20110294872A1 (en) * 2010-05-27 2011-12-01 The University Of Hong Kong High-affinity nucleic acid aptamers against sclerostin protein
CN102971424A (zh) * 2010-05-27 2013-03-13 香港大学 针对硬骨素蛋白质的高亲和力核酸适配体
CN104039828A (zh) * 2011-12-28 2014-09-10 安进公司 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Q. LYU: "\"Therapeutic potential of nucleic acid aptamers against sclerostin in the treatment of osteoporosis\"" *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454224A (zh) * 2019-02-11 2021-09-28 深圳欣沛生物医药技术服务有限公司 针对骨硬化蛋白的适体的诊断用途
WO2023046147A1 (zh) * 2021-09-26 2023-03-30 安沛治疗有限公司 针对dkk1的适体及其用途
CN114129587A (zh) * 2021-11-16 2022-03-04 北京大学口腔医学院 用于治疗骨质疏松症的纳米药物及其制备方法和应用
CN114129587B (zh) * 2021-11-16 2022-08-09 北京大学口腔医学院 用于治疗骨质疏松症的纳米药物及其制备方法和应用

Also Published As

Publication number Publication date
EP3754021A4 (en) 2021-11-10
CN111712573B (zh) 2023-10-20
US20210198672A1 (en) 2021-07-01
EP3754021A1 (en) 2020-12-23
JP2021513365A (ja) 2021-05-27
WO2019154410A1 (zh) 2019-08-15
JP7120531B2 (ja) 2022-08-17

Similar Documents

Publication Publication Date Title
CN111712573B (zh) 针对骨硬化蛋白的适体及其用途
US11583591B2 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
JP6587934B2 (ja) Ｐｄｇｆおよびｖｅｇｆ結合アプタマー、および、ｐｄｇｆおよびｖｅｇｆが介在する病気の治療へのそれらの使用
JP2021100439A (ja) Ｄｍｄのための複数のエキソンスキッピング組成物
US20190177723A1 (en) Compositions and methods for treating duchenne muscular dystrophy and related disorders
RU2477137C2 (ru) Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
AU2010284329B2 (en) Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
US9150862B2 (en) siRNA targeting VEGFA and methods for treatment in vivo
JP6949916B2 (ja) 安定性が向上したｐｄｇｆ及びｖｅｇｆアプタマー並びにｐｄｇｆ及びｖｅｇｆ媒介性の疾患及び障害の治療におけるそれらの使用
US10428330B2 (en) Stem-loop compositions and methods for inhibiting factor D
JP6987041B2 (ja) 脊髄性筋萎縮症におけるエクソン包含のための修飾アンチセンスオリゴマー
WO2022199685A1 (zh) 具有延长的体内半衰期的核酸分子缀合物
CN113454224A (zh) 针对骨硬化蛋白的适体的诊断用途
WO2020247850A1 (en) Compositions and methods for inhibiting angiopoietin-2
WO2023046147A1 (zh) 针对dkk1的适体及其用途
US20220098591A1 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growtn factor
US20210230599A1 (en) Stem-loop compositions and methods for inhibiting interleukin-8
AU2016204713B2 (en) Complement Binding Aptamers and Anti-C5 Agents Useful in the Treatment of Ocular Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230703

Address after: 101-103 M13, 1st Floor, 15W, No. 15, Science Park Road, Pak Shek Kok, New Territories, Hong Kong, China

Applicant after: Anpei treatment Co.,Ltd.

Address before: 2nd floor, West Wing, 822 Lai Chi Kok Road, Cheung Sha Wan, Kowloon, China

Applicant before: Anpei treatment Co.,Ltd.

Applicant before: Zhang Ge

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant